According to a recent market study published by Growth Market Reports, titled, “Global Intranasal Drug Delivery Devices Market – By Products, By Dosage, By Applications, By End-Users, By Distribution Channels, and By Regions: Size, Share, Trends and Opportunity Analysis, 2018-2028”, the market was valued at US$ 4,061.4 Million in 2020 and is expected to grow at a moderate growth rate of 6.5% by the year 2028. Increasing prevalence of chronic diseases, increasing focus on alternative routes such as Nasal drug delivery, and increasing awareness about intranasal drug delivery devices are expected to drive the market growth during the forecast period.

Request a free sample copy @ https://growthmarketreports.com/request-sample/4227

Nasal administration has been used for therapeutic purposes for centuries. The respiratory tract is a primary contact area for the environment and it represents a gateway for potential treatments and infectious particles such as viruses & bacteria. Intranasal administration is a non-invasive drug route of administration, widely used for the local treatment of nasal polyposis or rhinitis. In order to obtain effective and safe intranasal pharmaceutical products, a large number of strategies are applied to overcome nasal release barriers. In the design of a nasal product, three main cooperative entities must be considered: the administration device, the drug, and the delivery carrier. The nasal drug delivery pathway is an alternative route that gives access to the highly vascularized mucosa, which is exploited as an interesting site for the delivery of local drugs, the delivery of systemic medicines, and the delivery of targeted drugs (CNS). There are several nasal devices commercially available, such as nebulizers, syringes, and nasal sprays with specific properties based on administration technique and particle size.

The global intranasal drug delivery devices market is consolidated based on products, dosage, applications, end-users, distribution channels, and regions. On the basis of products, the global intranasal drug delivery devices market is segmented into powder delivery devices, liquid delivery devices, pressurized metered-dose inhalers, and others. Based on dosage, the global intranasal drug delivery devices market is segmented into unit-dose and multi-dose. In terms of applications, the global intranasal drug delivery devices market is segmented into respiratory disorders, neurological disorders, vaccination, pain management, and others. On the basis of end-users, the global intranasal drug delivery devices market is segmented into personal use, hospitals/clinics, and others. Based on distribution channels, the global intranasal drug delivery devices market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Based on regions the Global Intranasal Drug Delivery Devices market has been fragmented into Europe, North America, Asia Pacific, Latin America, and Middle East & Africa.

The intranasal drug delivery devices market is projected to witness a slight increase in year-on-year growth for 2020 as compared to the previous year 2019. regulatory bodies are anticipated to play a key role in boosting the market supporting the growth of the market in 2020. The intranasal drug delivery devices market is growing at a significant pace due to the growing pharmaceuticals industry expected to fuel the market.

As per Growth Market Reports industry analyst Raksha Sharma, “The global Intranasal Drug Delivery Devices market is anticipated to witness moderate growth during the forecast period 2020-2027. The intranasal drug delivery devices market is registering growth opportunities across the globe, owing to the development of over-the-counter drugs and increasing R&D activities”.

COVID-19 did not hamper the intranasal drug delivery devices market, as it is widely used in the pharmaceutical & healthcare sector. Manufacturers in the market were focused on investing in R&D activities, which drove the market during the pandemic. Growing R&D activities increased for nasal vaccination, which is expected to drive the market.

Key Takeaways from the Study:

  • The players include Johnson & Johnson, BD, Teva Pharmaceutical Industries Ltd, Nemera Development S.A., AptarGroup, Inc., and Recipharm AB among others hold a significant share of the Global Intranasal Drug Delivery Devices market in the year 2020.
  • The market in North America is projected to expand at a significant CAGR during the forecast period, owing to increasing government (U.S. FDA) approval for the use of intranasal drug delivery devices such as nasal sprays and nasal powder.
  • Based on distribution channels, the global intranasal drug delivery devices market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held a significant market share and is anticipated to grow in the coming years, owing to increasing focus on positive medical outcomes, patient awareness, and self-administration.

Report Scope:

Report Metric

Details

Market Value in 2020

US$ 4,061.4 Million

Market Growth Rate (from 2020 to 2028)

6.5%

Historical Data

2018, & 2019

Base Year

2020

Forecast Period

2021 - 2028

Units Considered

Value (US$ Million)

Market Segments

Products, Dosage, Applications, End-Users, Distribution Channels, & Regions

Regional Scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Key Companies Profiled

Teleflex Incorporated, AptarGroup, Inc., Johnson & Johnson, BD, Teva Pharmaceutical Industries Ltd, Vectura Group plc, Recipharm AB, H&T Presspart Manufacturing Ltd, Nemera Development S.A., OptiNose Inc, and Others

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail tailor-made purchase options to meet your research requirements.

 

Target Audience:

  • Supply-side: Manufacturers, raw material suppliers, and distributors
  • Demand Side: Hospitals/Clinics, Biotech and Pharmaceutical Industry, Academic and research institutes, Patients, and Others
  • Regulatory Side: Concerned government authorities, and other regulatory bodies such as European Medicines Agency (EMA) and Food and Drug Administration (FDA).